Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Breast Cancer | Review

Extrachromosomal circular DNA (eccDNA): from carcinogenesis to drug resistance

Authors: Zhaoxing Li, Daohai Qian

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Extrachromosomal circular DNA (eccDNA) is a circular form of DNA that exists outside of the chromosome. Although it has only been a few decades since its discovery, in recent years, it has been found to have a close relationship with cancer, which has attracted widespread attention from researchers. Thus far, under the persistent research of researchers from all over the world, eccDNA has been found to play an important role in a variety of tumors, including breast cancer, lung cancer, ovarian cancer, etc. Herein, we review the sources of eccDNA, classifications, and the mechanisms responsible for their biogenesis. In addition, we introduce the relationship between eccDNA and various cancers and the role of eccDNA in the generation and evolution of cancer. Finally, we summarize the research significance and importance of eccDNA in cancer, and highlight new prospects for the application of eccDNA in the future detection and treatment of cancer.
Literature
1.
Cortes J, Perez-García JM, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70(2):105–24.PubMedCrossRef
2.
3.
4.
5.
6.
7.
8.
Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013;152(6):1226–36.PubMedCrossRef
9.
Aguiar AP. Publishing large DNA sequence data in reduced spaces and lasting formats, in paper or PDF. Zootaxa. 2013;3609:593–600.PubMedCrossRef
10.
Møller HD, Mohiyuddin M, Prada-Luengo I, et al. Circular DNA elements of chromosomal origin are common in healthy human somatic tissue. Nat Commun. 2018;9(1):1069.PubMedPubMedCentralCrossRef
11.
12.
Wang M, Chen X, Yu F, Ding H, Zhang Y, Wang K. Extrachromosomal circular DNAs: origin, formation and emerging function in cancer. Int J Biol Sci. 2021;17(4):1010–25.PubMedPubMedCentralCrossRef
13.
14.
Qiu GH, Zheng X, Fu M, Huang C, Yang X. The decreased exclusion of nuclear eccDNA: from molecular and subcellular levels to human aging and age-related diseases. Ageing Res Rev. 2021;67: 101306.PubMedCrossRef
15.
Hull RM, King M, Pizza G, Krueger F, Vergara X, Houseley J. Transcription-induced formation of extrachromosomal DNA during yeast ageing. PLoS Biol. 2019;17(12):e3000471.PubMedPubMedCentralCrossRef
16.
Tandon I, Pal R, Pal JK, Sharma NK. Extrachromosomal circular DNAs: an extra piece of evidence to depict tumor heterogeneity. Future Sci OA. 2019;5(6):FSO390.PubMedPubMedCentralCrossRef
17.
Yang Y, Yang Y, Huang H, et al. PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration. Cell Death Dis. 2023;14(4):257.PubMedPubMedCentralCrossRef
18.
19.
Koche RP, Rodriguez-Fos E, Helmsauer K, et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma [published correction appears in Nat Genet. 2020 Feb 27]. Nat Genet. 2020;52(1):29–34.
20.
21.
deCarvalho AC, Kim H, Poisson LM, et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet. 2018;50(5):708–17.PubMedPubMedCentralCrossRef
22.
23.
Noer JB, Hørsdal OK, Xiang X, Luo Y, Regenberg B. Extrachromosomal circular DNA in cancer: history, current knowledge, and methods. Trends Genet. 2022;38(7):766–81.PubMedCrossRef
24.
Janssen A, Colmenares SU, Karpen GH. Heterochromatin: guardian of the genome. Annu Rev Cell Dev Biol. 2018;6(34):265–88.CrossRef
25.
Qiu GH, Zheng X, Fu M, Huang C, Yang X. The protective function of non-coding DNA in DNA damage accumulation with age and its roles in age-related diseases. Biogerontology. 2019;20(6):741–61.PubMedCrossRef
26.
Sin ST, Deng J, Ji L, Yukawa M, Chan RW, Volpi S, Vaglio A, Fenaroli P, Bocca P, Cheng SH, Wong DK, Lui KO, Jiang P, Chan KCA, Chiu RW, Lo YMD. Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight. 2022;7(8): e156070.PubMedPubMedCentralCrossRef
27.
Liao Z, Jiang W, Ye L, Li T, Yu X, Liu L. Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression. Biochim Biophys Acta Rev Cancer. 2020;1874(1): 188392.PubMedCrossRef
28.
Sin STK, Jiang P, Deng J, et al. Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proc Natl Acad Sci U S A. 2020;117(3):1658–65.PubMedPubMedCentralCrossRef
29.
30.
Dillon LW, Kumar P, Shibata Y, et al. Production of extrachromosomal MicroDNAs is linked to mismatch repair pathways and transcriptional activity. Cell Rep. 2015;11(11):1749–59.PubMedPubMedCentralCrossRef
31.
Selvarajah S, Yoshimoto M, Park PC, et al. The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma. 2006;115(6):459–67.PubMedCrossRef
32.
33.
Murnane JP, Sabatier L. Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays. 2004;26(11):1164–74.PubMedCrossRef
34.
Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40.PubMedPubMedCentralCrossRef
35.
36.
Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns [published correction appears in Nature. 2017 Feb 2;542(7639):124]. Nature. 2016;538(7625):378–382.
37.
Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589–93.PubMedCrossRef
38.
Fraser M, Sabelnykova VY, Yamaguchi TN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541(7637):359–64.PubMedCrossRef
39.
Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148(1–2):59–71.PubMedPubMedCentralCrossRef
40.
41.
Storlazzi CT, Lonoce A, Guastadisegni MC, et al. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res. 2010;20(9):1198–206.PubMedPubMedCentralCrossRef
42.
Barr FG, Nauta LE, Davis RJ, Schäfer BW, Nycum LM, Biegel JA. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet. 1996;5(1):15–21.PubMedCrossRef
43.
44.
45.
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.PubMedCrossRef
46.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021 Jul;71(4):359]. CA Cancer J Clin. 2021;71(1):7–33.
47.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
48.
49.
Kim H, Nguyen NP, Turner K, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020;52(9):891–7.PubMedPubMedCentralCrossRef
50.
Huh YO, Tang G, Talwalkar SS, et al. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet. 2016;209(7–8):313–20.PubMedCrossRef
51.
Wang N, Yuan L, Jing Y, et al. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations. Leuk Lymphoma. 2021;62(10):2466–74.PubMedCrossRef
52.
Zeng T, Huang W, Cui L, et al. The landscape of extrachromosomal circular DNA (eccDNA) in the normal hematopoiesis and leukemia evolution. Cell Death Discov. 2022;8(1):400.PubMedPubMedCentralCrossRef
53.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
54.
55.
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.PubMedCrossRef
56.
57.
Cen Y, Fang Y, Ren Y, Hong S, Lu W, Xu J. Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer. Cell Death Dis. 2022;13(4):342.PubMedPubMedCentralCrossRef
58.
Wu X, Li P, Yimiti M, et al. Identification and characterization of extrachromosomal circular DNA in plasma of lung adenocarcinoma patients. Int J Gen Med. 2022;15:4781–91.PubMedPubMedCentralCrossRef
59.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394–424.
60.
61.
Sun Z, Ji N, Zhao R, Liang J, Jiang J, Tian H. Extrachromosomal circular DNAs are common and functional in esophageal squamous cell carcinoma. Ann Transl Med. 2021;9(18):1464.PubMedPubMedCentralCrossRef
62.
Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for neuroblastoma: progress and challenges [published correction appears in Med Res Rev. 2022 Jan;42(1):641]. Med Res Rev. 2021;41(2):961–1021.
63.
Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschellà G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 2015;6(12):e2010.PubMedPubMedCentralCrossRef
64.
Valent A, Bénard J, Clausse B, et al. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol. 2001;158(5):1579–84.PubMedPubMedCentralCrossRef
65.
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.PubMedCrossRef
66.
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.PubMedCrossRef
67.
Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309–18.PubMedCrossRef
68.
Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008;58(6):261–4.PubMed
69.
70.
Shimizu N. Gene amplification and the extrachromosomal circular DNA. Genes (Basel). 2021;12(10):1533. Published 2021 Sep 28.
71.
Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics. 2009;93(1):17–21.PubMedCrossRef
72.
Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–17.PubMed
73.
74.
Navrátilová A, Koblízková A, Macas J. Survey of extrachromosomal circular DNA derived from plant satellite repeats. BMC Plant Biol. 2008;22(8):90.CrossRef
75.
Joly JR, Winn WC. Legionella pneumophila subgroups, monoclonal antibody reactivity, and strain virulence in Burlington, Vermont. J Infect Dis. 1988;158(6):1412.PubMedCrossRef
76.
Shibata Y, Kumar P, Layer R, Willcox S, Gagan JR, Griffith JD, Dutta A. Extrachromosomal microDNAs and chromosomal microdeletions in normal tissues. Science. 2012;336(6077):82–6.PubMedPubMedCentralCrossRef
77.
Møller HD, Parsons L, Jørgensen TS, Botstein D, Regenberg B. Extrachromosomal circular DNA is common in yeast. Proc Natl Acad Sci U S A. 2015;112(24):E3114–22.PubMedPubMedCentralCrossRef
78.
Shoura MJ, Gabdank I, Hansen L, Merker J, Gotlib J, Levene SD, Fire AZ. Intricate and cell type-specific populations of endogenous circular DNA (eccDNA). In: Caenorhabditis elegans and Homo sapiens G3 (Bethesda). 2017;7(10):3295–3303.
79.
Møller HD. Circle-Seq: isolation and sequencing of chromosome-derived circular DNA elements in cells. Methods Mol Biol. 2020;2119:165–81.PubMedCrossRef
80.
Gebhart E. Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia—a review. Clin Transl Oncol. 2005;7(11):477–85.PubMedCrossRef
Metadata
Title
Extrachromosomal circular DNA (eccDNA): from carcinogenesis to drug resistance
Authors
Zhaoxing Li
Daohai Qian
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-024-01348-6

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue

Research

Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort

Research

Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome

Research

Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.

Review

Recent nanotheranostic approaches in cancer research

Research

An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma

Research

The demographic, laboratory and genetic factors associated with long Covid-19 syndrome: a case–control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits